$31.49
0.0% Today
as of Jul 22, 16:47 ET
Last 30 days
Recent Press Releases & News
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
CPRX: What does Argus have to say about CPRX?
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger
Overview
52-week range
$19
$33
92% of range
Avg surprise (last 3)
+21.3%
Avg reaction (last 2)
+0.9%
50% positive
Latest IV / EM
161%
EM ±9.5% · $30 · Jul 17
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 11, 2026 | Mar/2026 | $0.74 | $0.58 | +27.6% | +17.5% | 0.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.42 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $0.62 | $0.55 | +12.7% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $0.63 | $0.51 | +23.5% | — | +1.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.35 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.33 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.19 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.29 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.33 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 5, 2026 | Jun/2026 | OTHER | $0.63 | $0.62 | +1.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $73M | — | $66M | $66M | $63M | — | $51M | $54M |
| Net income | $64M | — | $53M | $52M | $57M | — | $44M | $41M |
| EPS (diluted) | $0.50 | — | $0.42 | $0.41 | $0.45 | — | $0.35 | $0.33 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $756M | $709M | $690M | $653M | $581M | $518M | $442M | $376M |
| Inventory | $35M | $37M | $28M | $19M | $20M | $20M | $20M | $18M |
| Total current assets | $940M | $894M | $852M | $759M | $686M | $624M | $539M | $474M |
| Total assets | $1.15B | $1.10B | $1.05B | $972M | $909M | $851M | $772M | $706M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $135M | $150M | $131M | $116M | $115M | $124M | $111M | $98M |
| Total equity | $1.01B | $954M | $920M | $856M | $794M | $728M | $661M | $609M |